Elanco rises 8.7% after quarterly beat and outlook raise

What happened

Elanco (ELAN) rose 8.7% on November 6, 2026, after reporting third-quarter results that topped expectations and raising its full-year outlook. The company, with a market value of $12.86 billion, said an earnings surprise and the guidance lift drove the session’s move. Management held an earnings call on November 6, 2026, featuring CEO Jeffrey Simmons and CFO Robert VanHimbergen and discussed revenue growth led by demand for pet products Zenrelia and Credelio Quattro and higher pricing across its portfolio.

How big was the move

The stock’s closing price was $25.74, and the day’s jump was 3.7 times a typical daily move for this stock. Trading volume was 2.3 times its 20-day average, reflecting heavier activity than normal, while the S&P 500 rose 0.3% on the day. Over the last five sessions the stock rose 11.6% as the S&P 500 over five sessions fell 2.7%, leaving the stock’s five-day advance 6.8 percentage points better than the Healthcare sector median on the day.

In context, the session was not unique for size: in the past five years the stock had 9 sessions with a gain of at least 8.7%. Twenty trading days after those sessions the median result was a gain of 8.2% and 6 of 9 were higher. That historical pattern shows similar-sized moves have often carried further gains in the near term, although past performance is not predictive.

The technical picture

Technically, the stock sat 10.3% above its 20-day moving average, 11.3% above its 50-day moving average and 8.2% above its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend despite recent strength. The Relative Strength Index (14 days) read 65, inside a neutral range between 30 and 70, indicating momentum is not yet overbought.

Shares were 8.0% below the 52-week high and had risen 14.2% over one month and 15.5% over three months, leaving one-year performance up 19.2% and 10.6 percentage points ahead of the S&P 500. Volatility measured 37% annualized over 60 days, lower than 72% of its own readings over five years, indicating recent volatility below much of its historical range.

Fundamentals and valuation

For the four quarters through September 30, 2026, revenue was $5.15 billion, which grew 12.1% from a year earlier and was roughly in line with growth from the prior quarter of 12.0%. Diluted earnings per share over that period were $-0.29, a result that fell 539.4% from a year earlier as the company works on margin recovery after prior losses. Gross margin expanded to 53.5% from 46.4% a year earlier while operating margin improved to 10.0% from 5.2%.

Free-cash-flow margin was 7.9% and return on invested capital was 3.9%, metrics that signal improving cash generation but modest returns relative to peers. The balance sheet carried net debt of 4.8 times EBITDA, and share count over one year increased by 2.0%. Those balance-sheet measures were highlighted on the call as the company balances investment with debt reduction.

On valuation, the stock traded at 22.7 times expected earnings on a price to forward earnings basis, with a free-cash-flow yield of 3.5%. PromtFinance scores rank Value at 79 (Positive) and Growth at 28 (Very weak), with Quality at 60 (Neutral) and Momentum and Revisions both at 64 (Neutral). The mix of a high Value score and weak Growth suggests the market prices in slower long-term growth even as valuation appears moderate.

Earnings and analyst expectations

The last report on November 6, 2026, showed earnings per share of $0.27 against $0.20 expected, 33.1% above estimates. That marked the seventh consecutive quarter beating estimates and an average surprise over the last four reports of 23.3% above estimates. Typical two-day reactions after recent reports have been a rise of 8.5%.

Analysts covering the name number 22, with 68% rating the stock Buy or Strong Buy and a consensus rating of Buy. The consensus price target was $26.67, 3.6% above the closing price. The next report is scheduled for February 23, 2027.

Recent company commentary attributed the stronger-than-expected quarter to volume gains in key pet product lines and pricing actions across the portfolio. The Q3 earnings call and transcript, reported by Seeking Alpha and MarketBeat, included discussion of the full-year outlook increase and operational execution behind margin improvement.

What to watch

• Next report: February 23, 2027
• Last report: November 6, 2026 — EPS $0.27 vs $0.20 expected, 33.1% above estimates
• Consensus price target: $26.67, 3.6% above the closing price
• Analysts covering the stock: 22, with 68% rating Buy or Strong Buy
• Balance sheet metric: net debt of 4.8 times EBITDA